Cargando…
Ferroptosis: Reviewing CRC with the Third Eye
Colorectal cancer (CRC) has been one of the most common cancers and maintains the second-highest incidence and mortality rates among all cancers. The high risk of recurrence and metastasis and poor survival are still huge challenges in CRC therapy, in which the discovery of ferroptosis provides a no...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790162/ https://www.ncbi.nlm.nih.gov/pubmed/36575747 http://dx.doi.org/10.2147/JIR.S389290 |
_version_ | 1784859113262415872 |
---|---|
author | Liu, Xingyu Tuerxun, Halahati Li, Yawen Li, Yaping He, Yuanyuan Zhao, Yuguang |
author_facet | Liu, Xingyu Tuerxun, Halahati Li, Yawen Li, Yaping He, Yuanyuan Zhao, Yuguang |
author_sort | Liu, Xingyu |
collection | PubMed |
description | Colorectal cancer (CRC) has been one of the most common cancers and maintains the second-highest incidence and mortality rates among all cancers. The high risk of recurrence and metastasis and poor survival are still huge challenges in CRC therapy, in which the discovery of ferroptosis provides a novel perspective. It has been ten years since a unique type of regulated cell death driven by iron accumulation and lipid peroxidation was proposed and named ferroptosis. During the past decade, there have been multiple pieces of evidence suggesting that ferroptosis participates in the pathophysiological processes during disease progression. In this review, we describe ferroptosis as an imbalance of oxidant systems and anti-oxidants which results in lipid peroxidation, membrane damage, and finally cell death. We elaborate on the mechanisms of ferroptosis and systematically summarize recent studies on the regulatory pathways of ferroptosis in CRC from various perspectives, ranging from encoding genes, noncoding RNAs to regulatory proteins. Finally, we discuss the potential therapeutic role of ferroptosis in CRC treatments. |
format | Online Article Text |
id | pubmed-9790162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-97901622022-12-26 Ferroptosis: Reviewing CRC with the Third Eye Liu, Xingyu Tuerxun, Halahati Li, Yawen Li, Yaping He, Yuanyuan Zhao, Yuguang J Inflamm Res Review Colorectal cancer (CRC) has been one of the most common cancers and maintains the second-highest incidence and mortality rates among all cancers. The high risk of recurrence and metastasis and poor survival are still huge challenges in CRC therapy, in which the discovery of ferroptosis provides a novel perspective. It has been ten years since a unique type of regulated cell death driven by iron accumulation and lipid peroxidation was proposed and named ferroptosis. During the past decade, there have been multiple pieces of evidence suggesting that ferroptosis participates in the pathophysiological processes during disease progression. In this review, we describe ferroptosis as an imbalance of oxidant systems and anti-oxidants which results in lipid peroxidation, membrane damage, and finally cell death. We elaborate on the mechanisms of ferroptosis and systematically summarize recent studies on the regulatory pathways of ferroptosis in CRC from various perspectives, ranging from encoding genes, noncoding RNAs to regulatory proteins. Finally, we discuss the potential therapeutic role of ferroptosis in CRC treatments. Dove 2022-12-21 /pmc/articles/PMC9790162/ /pubmed/36575747 http://dx.doi.org/10.2147/JIR.S389290 Text en © 2022 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Liu, Xingyu Tuerxun, Halahati Li, Yawen Li, Yaping He, Yuanyuan Zhao, Yuguang Ferroptosis: Reviewing CRC with the Third Eye |
title | Ferroptosis: Reviewing CRC with the Third Eye |
title_full | Ferroptosis: Reviewing CRC with the Third Eye |
title_fullStr | Ferroptosis: Reviewing CRC with the Third Eye |
title_full_unstemmed | Ferroptosis: Reviewing CRC with the Third Eye |
title_short | Ferroptosis: Reviewing CRC with the Third Eye |
title_sort | ferroptosis: reviewing crc with the third eye |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790162/ https://www.ncbi.nlm.nih.gov/pubmed/36575747 http://dx.doi.org/10.2147/JIR.S389290 |
work_keys_str_mv | AT liuxingyu ferroptosisreviewingcrcwiththethirdeye AT tuerxunhalahati ferroptosisreviewingcrcwiththethirdeye AT liyawen ferroptosisreviewingcrcwiththethirdeye AT liyaping ferroptosisreviewingcrcwiththethirdeye AT heyuanyuan ferroptosisreviewingcrcwiththethirdeye AT zhaoyuguang ferroptosisreviewingcrcwiththethirdeye |